AAminove
Back to library

Cagrilintide

Human observational

Also known as: AM833, part of CagriSema

Metabolic / fat-lossWeight management (investigational)

Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.

Overview

An investigational long-acting amylin analogue, studied alone and combined with semaglutide (CagriSema). Not yet approved.

Mechanism

Amylin-receptor agonism that promotes satiety and slows gastric emptying, complementary to GLP-1 agonists.

Evidence

Human observationalWhat does this mean?

Phase 2 human data exist; investigational, not approved.

Community-reported information

Investigational and unapproved outside trials.

General information only, not tailored to you and not a recommendation. Some regions withhold this entirely.

Half-life

~7 days (once-weekly dosing in trials).

Storage

Refrigerate per trial protocols.

Commonly reported side effects

  • Nausea
  • Vomiting
  • Decreased appetite

Legal status by region

  • USInvestigational; not FDA-approved.

Legal status changes over time; verify locally before relying on this.

Citations